Literature DB >> 30185813

JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity.

Yan Liu1,2, Yue-Hong Long1, Shu-Qing Wang3, Yuan-Yue Zhang1,2, Yu-Feng Li2, Jiang-Sheng Mi4, Cheng-Hua Yu4, De-Yan Li4, Jing-Hua Zhang5, Xiao-Jun Zhang6.   

Abstract

Overexpression of Jumonji domain-containing 6 (JMJD6) has been reported to be associated with more aggressive breast cancer characteristics. However, the precise role of JMJD6 in breast cancer development remains unclear. Here, we demonstrate that JMJD6 has intrinsic tyrosine kinase activity and can utilize ATP and GTP as phosphate donors to phosphorylate Y39 of histone H2A.X (H2A.XY39ph). High JMJD6 levels promoted autophagy in triple negative breast cancer (TNBC) cells by regulating the expression of autophagy-related genes. The JMJD6-H2A.XY39ph axis promoted TNBC cell growth via the autophagy pathway. We show that combined inhibition of JMJD6 kinase activity and autophagy efficiently decreases TNBC growth. Together, these findings suggest an effective strategy for TNBC treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30185813     DOI: 10.1038/s41388-018-0466-y

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Mutation of actin Tyr-53 alters the conformations of the DNase I-binding loop and the nucleotide-binding cleft.

Authors:  Xiong Liu; Shi Shu; Myoung-Soon S Hong; Bin Yu; Edward D Korn
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

2.  New DNA sequence rules for high affinity binding to histone octamer and sequence-directed nucleosome positioning.

Authors:  P T Lowary; J Widom
Journal:  J Mol Biol       Date:  1998-02-13       Impact factor: 5.469

3.  Casein kinase II.

Authors:  G M Hathaway; J A Traugh
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

4.  Phosphorylation of H2A.XTyr39 positively regulates DNA damage response and is linked to cancer progression.

Authors:  Yan Liu; Yue-Hong Long; Shu-Qing Wang; Yu-Feng Li; Jing-Hua Zhang
Journal:  FEBS J       Date:  2016-11-23       Impact factor: 5.542

5.  An optimized protocol for protein purification in cultured mammalian cells using a tandem affinity purification approach.

Authors:  Arthur Tsai; Russ P Carstens
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

6.  Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.

Authors:  Sylvain Lefort; Carine Joffre; Yann Kieffer; Anne-Marie Givel; Brigitte Bourachot; Giulia Zago; Ivan Bieche; Thierry Dubois; Didier Meseure; Anne Vincent-Salomon; Jacques Camonis; Fatima Mechta-Grigoriou
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

7.  Proteomic analysis of nucleoporin interacting proteins.

Authors:  N P Allen; L Huang; A Burlingame; M Rexach
Journal:  J Biol Chem       Date:  2001-05-31       Impact factor: 5.157

8.  Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing.

Authors:  Celia J Webby; Alexander Wolf; Natalia Gromak; Mathias Dreger; Holger Kramer; Benedikt Kessler; Michael L Nielsen; Corinna Schmitz; Danica S Butler; John R Yates; Claire M Delahunty; Phillip Hahn; Andreas Lengeling; Matthias Mann; Nicholas J Proudfoot; Christopher J Schofield; Angelika Böttger
Journal:  Science       Date:  2009-07-03       Impact factor: 47.728

9.  Genomic structure and expression of Jmjd6 and evolutionary analysis in the context of related JmjC domain containing proteins.

Authors:  Phillip Hahn; Jens Böse; Stefanie Edler; Andreas Lengeling
Journal:  BMC Genomics       Date:  2008-06-18       Impact factor: 3.969

10.  Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.

Authors:  Shaokun Shu; Charles Y Lin; Housheng Hansen He; Robert M Witwicki; Doris P Tabassum; Justin M Roberts; Michalina Janiszewska; Sung Jin Huh; Yi Liang; Jeremy Ryan; Ernest Doherty; Hisham Mohammed; Hao Guo; Daniel G Stover; Muhammad B Ekram; Jonathan Brown; Clive D'Santos; Ian E Krop; Deborah Dillon; Michael McKeown; Christopher Ott; Jun Qi; Min Ni; Prakash K Rao; Melissa Duarte; Shwu-Yuan Wu; Cheng-Ming Chiang; Lars Anders; Richard A Young; Eric Winer; Antony Letai; William T Barry; Jason S Carroll; Henry Long; Myles Brown; X Shirley Liu; Clifford A Meyer; James E Bradner; Kornelia Polyak
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

View more
  22 in total

Review 1.  The small members of the JMJD protein family: Enzymatic jewels or jinxes?

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-26       Impact factor: 10.680

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

3.  Genetic Regulation of Neuronal Progranulin Reveals a Critical Role for the Autophagy-Lysosome Pathway.

Authors:  Lisa P Elia; Amanda R Mason; Amela Alijagic; Steven Finkbeiner
Journal:  J Neurosci       Date:  2019-01-29       Impact factor: 6.167

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

5.  An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma.

Authors:  Jin Zhou; Jeremy M Simon; Chengheng Liao; Cheng Zhang; Lianxin Hu; Giada Zurlo; Xijuan Liu; Cheng Fan; Austin Hepperla; Liwei Jia; Vanina Toffessi Tcheuyap; Hua Zhong; Roy Elias; Jin Ye; W Mike Henne; Payal Kapur; Deepak Nijhawan; James Brugarolas; Qing Zhang
Journal:  Mol Cell       Date:  2022-06-27       Impact factor: 19.328

Review 6.  Approaches to develop therapeutics to treat frontotemporal dementia.

Authors:  Lisa P Elia; Terry Reisine; Amela Alijagic; Steven Finkbeiner
Journal:  Neuropharmacology       Date:  2020-01-08       Impact factor: 5.250

7.  JMJD6 participates in the maintenance of ribosomal DNA integrity in response to DNA damage.

Authors:  Jérémie Fages; Catherine Chailleux; Jonathan Humbert; Suk-Min Jang; Jérémy Loehr; Jean-Philippe Lambert; Jacques Côté; Didier Trouche; Yvan Canitrot
Journal:  PLoS Genet       Date:  2020-06-29       Impact factor: 5.917

8.  JMJD6 Dysfunction Due to Iron Deficiency in Preeclampsia Disrupts Fibronectin Homeostasis Resulting in Diminished Trophoblast Migration.

Authors:  Sruthi Alahari; Abby Farrell; Leonardo Ermini; Chanho Park; Julien Sallais; Sarah Roberts; Taylor Gillmore; Michael Litvack; Martin Post; Isabella Caniggia
Journal:  Front Cell Dev Biol       Date:  2021-05-12

Review 9.  Jumonji domain-containing protein 6 protein and its role in cancer.

Authors:  Jing Yang; Siyuan Chen; Yanfei Yang; Xuelei Ma; Bin Shao; Shengyong Yang; Yuquan Wei; Xiawei Wei
Journal:  Cell Prolif       Date:  2020-01-21       Impact factor: 6.831

10.  Jumonji domain-containing protein 6 functions as a marker of head and neck squamous cell carcinoma at advanced stage with no effect on prognosis.

Authors:  Bing Guo; Lei Wang; Xingjun Qin; Yi Shen; Chunyue Ma
Journal:  Oncol Lett       Date:  2019-09-30       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.